Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The supplements are made using only vegetarian-sourced ingredients
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
Subscribe To Our Newsletter & Stay Updated
